Clinical trials: Primary Sjögren's Syndrome (pSS)
Primary Sjögren Syndrome
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
This is a first exploration of GLPG3970 in participants with active primary Sjogren's Syndrome (pSS) to evaluate the efficacy, safety and tolerability and to determine its pharmacokinetics (PK) profile compared to placebo.
- Trial name
- GLIDER (NCT04700280)
- Testing
- GLPG3970
- Where
- 10 sites in Germany, Greece and 3 more
- Volunteers
- 31 people
- Sponsor
- Lakefront Biotherapeutics NV
Primary Sjögren's Syndrome
A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)
The purpose of this study is to assess the efficacy and safety of human FcRn blocking therapy with efgartigimod compared to placebo, in participants with pSS.
- Trial name
- rho (NCT05817669)
- Testing
- Efgartigimod
- Where
- 17 sites in Belgium, Hungary and 2 more
- Volunteers
- 34 people
- Sponsor
- argenx
Primary Sjögren's Syndrome
Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
Efgartigimod has the potential to improve disease manifestations by the reduction of IgG autoantibodies in Sjogren's Syndrome (SjD or pSS).
- Trial name
- Rho plus (NCT06203457)
- Testing
- Efgartigimod
- Where
- 11 sites in Belgium, Hungary and 1 more
- Volunteers
- 24 people
- Sponsor
- argenx
Primary Sjögren Syndrome
Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome
This pilot study will make a preliminary determination of the safety of ustekinumab in patients with Primary Sjogren's Syndrome (PSS) and assess the response of systemic measures of inflammation (biomarkers).
- Trial name
- NCT04093531
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Rochester
Autoimmune Diseases
A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts
This is a pilot imaging study to determine whether molecular imaging with 18^F fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), 11^C-Methionine (MET) PET/CT, and salivary gland magnetic…
- Trial name
- NCT02899377
- Testing
- 18F-FDG PET/CT Imaging, 11C-MET PET/CT Imaging, MRI Imaging with intravenous contrast with gadoterate meglumine
- Where
- 4 sites in United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline